Revista de la Sociedad Argentina de Diabetes
DIABETES TIPO 1 E INSULINORRESISTENCIA: TASA ESTIMADA DE DISPOSICIÓN DE LA GLUCOSA Y SU CORRELACIÓN CON COMPLICACIONES CRÓNICAS
Resumen
Introducción: la insulinorresistencia (IR) en diabetes tipo 1 (DM1) se asocia a mayor riesgo de complicaciones. El gold standard para evaluar insulinosensibilidad (IS) es el clamp euglucémico-hiperinsulinémico, aunque no se utiliza en la práctica clínica. La tasa estimada de disposición de la glucosa (TeDG) ha sido validada para estimar IS en DM1.
Objetivos: relacionar IR en DM1 (TeDG) con complicaciones macro y microvasculares en pacientes asistidos en un Servicio de Diabetología.
Materiales y métodos: se realizó un estudio transversal. La TeDG fue calculada utilizando HbA1c, perímetro de cintura y presencia de hipertensión.
Palabras clave
Texto completo:
PDFReferencias
Ginsberg HN. Investigation of insulin sensitivity in treated subjects with ketosis-prone diabetes mellitus. Diabetes 1977; 26: 278-283.
DeFronzo RA, Simonson D, Ferrannini E. Hepatic and peripheral insulin resistance: a common feature of type 2 (non-insulindependent) and type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1982; 23:313-319.
DeFronzo RA, Hendler R, Simonson D. Insulin resistance is a prominent feature of insulin-dependent diabetes. Diabetes 1982; 31:795-801.
Chillarón JJ, Flores-Le-Roux JA, Goday A, et al. Metabolic syndrome and type-1 diabetes mellitus: prevalence and associated factors. Rev Esp Cardiol 2010; 63:423- 429
Thorn LM, Forsblom C, Fagerudd J, et al; FinnDiane Study Group. Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane Study). Diabetes Care 2005; 28:2019-2024.
Rodrigues TC, Canani LH, Gross JL. Metabolic syndrome, insulinresistance and cardiovascular disease in type-1 diabetes mellitus. Arq Bras Cardiol 2010;94: 134-139.
Libman IM, Becker DJ. Coexistence of type 1 and type 2 diabetes mellitus: “double” diabetes? Pediatr Diabetes 2003; 4:110-113.
Gilliam LK, Brooks-Worrell BM, Palmer JP, et al. Autoimmunity and clinical course in children with type 1, type 2, and type 1.5 diabetes. J Autoimmun 2005; 25:244-250.
Williams KV, Erbey JR, Becker D, et al. Can clinical factors estimate insulin resistance in type 1 diabetes? Diabetes 2000; 49:626-632.
Chillarón JJ, Goday A, Flores-Le-Roux JA, et al. Estimated glucose disposal rate in assessment of the metabolic syndrome and microvascular complications in patients with type 1 diabetes. J Clin Endocrinol Metab 2009; 94:3530-3534.
Epstein EJ, Osman JL. Use of the estimated glucose disposal rate as a measure of insulin resistance in an urban multiethnic population with type 1 diabetes. Diabetes Care 2013; 36: 2280-2285.
Tercera Encuesta Nacional de Factores de Riesgo para Enfermedades No Transmisibles. Disponible en: www.indec.gov.ar/bajarPublicacion.asp?idc=3CA3D716DACD1FEED191A1BE551949F175343FDAFF106A623D694B04340DC484EA3967340FD9212F. Argentina 2013. www.msal.gob.ar/images/stories/bes/graficos/0000000544cnt-2015_09_04_encuesta_nacional_factores_riesgo.pdf
Levey AS, Bosch JP. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease Study Group. Ann Intern Med 1999 Mar 16; 130(6):461-70.
American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care 2014 Jan; 37 (Supplement 1): S14-S80.
Office of Disease Prevention and HealthPromotion, U.S. Department of Health and Human Services 2014. Disponible en: www.health.gov/paguidelines/guidelines/default.aspx.
Alberti K, Zimmet P. The metabolic syndrome a new world wide definition. Lancet 2005; 366 (9491):1059-1062.
Diabetic Retinopathy: a position statement by the American Diabetes Association. Diabetes Care 2017; 40:412-418.
American Diabetes Association. Consensus development conference on the diagnosis and management of nephropathy in patients with diabetes mellitus. Diabetes Care 1994; 17:1357.
Dyck PJ. Approches to improve epidemiological studies of diabetic neuropathy. Diabetes 1997; S5-S13.
The DCCT Research Group. Weight gain associated with intensive therapy in the diabetes control and complications trial. Diabetes Care 1988, 11:567-573.
Libman IM, Pietropaolo M. Changing prevalence of overweight children and adolescents at onset of insulintreated diabetes. Diabetes Care 2003, 26:2871-2875.
Minges KE, Whittemore R, Grey M. Overweight and obesity in youth with type 1 diabetes. Annu Rev Nurs Res 2013; 31:47-69.
Chillarón JJ, Flores Le-Roux JA. Type 1 diabetes, metabolic syndrome and cardiovascular risk. Metabolism 2014; 63:181-187.
Leroux C, Brazeau AS, Gingras V, et al. Lifestyle and cardiometabolic risk in adults with type 1 diabetes: a review. Can J Diabetes 2014; 38:62-69.
Merger SR, Leslie RD. The broad clinical phenotype of type 1 diabetes at presentation. Diabet Med 2013; 30:170-8.
Merger SR, Kerner W. Prevalence and comorbidities of double diabetes. Diabetes research and clinical practice 2016; 119, 48-56.
Intensive Diabetes Management. Implications of the DCCT and UKPDS. Diabetes Educ 2002; 28:735-40.
Thorn L, Forsblom C. Effect of parental type 2 diabetes on offspring with type 1 diabetes. Diabetes Care 2009; 32:63-68.
Martin FI, Stocks AE. Insulin sensitivity and vascular disease in insulin-dependent diabetics. Br Med J 1968; 2:81-82.
Chillarón JJ, Flores-Le-Roux JA. Síndrome metabólico y diabetes mellitus tipo 1: prevalencia y factores relacionados. Rev Esp Cardiol 2010; 63(4):423-9.
Orchard TJ, Olson JC. Insulin resistance related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10- year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 2003; 26:1374-1379.
Kilpatrick E, Rigby A, et al. Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes “double diabetes” in the Diabetes Control and Complications Trial. Diabetes Care 2007; 30:707-712.
Thorn LM, Forsblom C. The FinnDiane Study Group: metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care 2005; 28:2019-2024.
Yip J, Matlock MB. Insulin resistance in insulin-dependent diabetic patients with microalbuminuria. Lancet 1993; 342:883-887.
Orchard T, Chang Y, Ferrell R, et al. Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities? Further evidence from the Pittsburgh Epidemiology of Diabetes Complication Study. Kidney International 2002; Vol. 62, 963-970.
Bjornstad P, Maahs M. Estimated insulin sensitivity predicts regression of albuminuria in type 1 diabetes. Diabet Med 2015 Fe; 32(2): 257-261.
Olson JC, Erbey JR, Williams KV. Subclinical atherosclerosis and estimated glucose disposal rate as predictors of mortality in type 1 diabetes. Ann Epidemiol 2002; 12:331-337.
DOI: http://dx.doi.org/10.47196/diab.v51i2.53
Copyright (c) 2018 Revista de la Sociedad Argentina de Diabetes (SAD) - Versión de prueba
